Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, highlights the rationale and results of a retrospective study investigating whether hospital-based outpatient management is safe and feasible for patients receiving anti-BCMA CAR-T therapy for multiple myeloma, axicabtagene ciloleucel (axi-cel) for follicular lymphoma (FL), and brexucabtagene maraleucel (brexu-cel) for mantle cell lymphoma (MCL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.